University of California San Francisco; San Francisco, CA USA; Department of Medical Sciences; Section of Dermatology; University of Turin; Turin, Italy.
University of California San Francisco; San Francisco, CA USA; The Rudolfstiftung Hospital; Vienna, Austria.
Cancer Biol Ther. 2014 Jun 1;15(6):665-74. doi: 10.4161/cbt.28555. Epub 2014 Mar 20.
Immunotherapy is a cornerstone in the treatment of melanoma, and is intended to modulate the host immunity against the tumor. Immunotherapy can be used in an adjuvant setting, after complete surgical excision in patients with a high risk of disease relapse and as a treatment in advanced (unresectable or metastatic) stages. Development of novel therapeutic approaches and the optimization of existing therapies hold a great promise in the field of melanoma therapy research. Different clinical trials are ongoing, and immunotherapy is showing the ability to confirm durable clinical benefits in selected groups of melanoma patients. The aim of this review is to summarize different types of immunotherapy agents, as well as to discuss different strategies, complementary regimens, and possible biomarkers of response to the treatment.
免疫疗法是治疗黑色素瘤的基石，旨在调节宿主对肿瘤的免疫。免疫疗法可用于辅助治疗，在高疾病复发风险的患者完全手术切除后使用，也可用于晚期（不可切除或转移性）阶段的治疗。在黑色素瘤治疗研究领域，开发新的治疗方法和优化现有疗法具有很大的前景。不同的临床试验正在进行中，免疫疗法显示出在选定的黑色素瘤患者群体中能够确认持久的临床获益的能力。本文的目的是总结不同类型的免疫治疗药物，并讨论不同的策略、互补方案和可能的治疗反应生物标志物。
